|
業務類別
|
Medical Devices |
|
業務概覽
|
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic andeither do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA. |
| 公司地址
| 700 Chesapeake Drive, Redwood, CA, USA, 94063 |
| 電話號碼
| +1 650 364-0400 |
| 傳真號碼
| +1 650 364-0403 |
| 公司網頁
| https://www.pulmonx.com |
| 員工數量
| 296 |
| Mr. David A. Lehman |
General Counsel |
美元 472.40K |
22/04/2026 |
| Mr. Srikanth Radhakrishnan |
Chief Scientific Officer and Chief Technology Officer |
-- |
22/04/2026 |
| Mr. Geoffrey Beran Rose |
Chief Commercial Officer |
-- |
22/04/2026 |
| Mr. Glendon E. French |
Director, President and Chief Executive Officer |
美元 116.19K |
22/04/2026 |
| Dr. Derrick Sung, PhD |
Principal Accounting Officer, Chief Operating Officer and Chief Financial Officer |
美元 83.33K |
22/04/2026 |
|
|
| Mr. Dana G. Mead, Jr |
Non-Executive Chairman of the Board |
22/04/2026 |
| Mr. Daniel P. Florin |
Independent Director |
22/04/2026 |
| Mr. Thomas W. Burns |
Independent Director |
22/04/2026 |
| Ms. Georgia Garinois-Melenikiotou |
Independent Director |
22/04/2026 |
| Mr. Glendon E. French |
Director, President and Chief Executive Officer |
22/04/2026 |
| Mr. Richard M. Ferrari |
Independent Director |
22/04/2026 |
| Ms. Tiffany Sullivan |
Independent Director |
22/04/2026 |
|
|
|
|
